DynaGen, Alpharma deal

The companies signed a definitive agreement under which DYGN will purchase the tablet business of Alpharma's Able Laboratories Inc. unit, a generic pharmaceutical products subsidiary, for $550,000. DYGN will acquire the rights to 10 ANDA products through the acquisition. The tablet business, which was not profitable, had revenues of $2.5 million in 1995. Able, which manufactures and markets prescription and over-the-counter drugs, has 46,000-square feet of manufacturing space with 45 employees. ...